Tumor tissue dissociation liquid, method for dissociating tumor tissue and application of dissociation liquid in culturing tumor organoid

By using tumor tissue dissociation fluid containing antioxidants and dissociation enzymes, combined with the double-layer sleeve filter technology, the problem of limitations of cell damage and two-dimensional culture models in traditional methods is solved, and efficient and accurate tumor cell dissociation is achieved. The construction of ion and organoids simulates the three-dimensional structure and biological characteristics of tumors in vivo.

CN119060955AInactive Publication Date: 2024-12-03BIOGENOUS BIOTECH INC

Patent Information

Application Number
CN202411554353.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-11-04
Publication Date
2024-12-03
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Traditional tumor tissue dissociation methods are prone to destroy the biological characteristics of cells, making it difficult to obtain high-quality cell samples, and the two-dimensional cell culture model cannot truly simulate the tumor microenvironment in vivo.

Method used

Using a tumor tissue dissociation solution, the liquid includes basal medium, antioxidant components (taurine, superoxide dismutase and vitamin E), dissociation enzymes (collagen hydrolase, neutral protease and deoxyribose nucleases) and additives (HEPES, bovine serum albumin and Y27632) to improve dissociation efficiency and cell activity, and cell filtration and culture through a double-layer sleeve filter.

Benefits of technology

It improves the activity and separation efficiency of tumor cells, reduces cell damage, and successfully simulates the three-dimensional structure and biological characteristics of tumors in the body, providing efficient and accurate tools for tumor research.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119060955A_ABST
    Figure CN119060955A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of organoid culture. The invention provides a tumor tissue dissociation liquid, a tumor tissue dissociation method and application of the tumor tissue dissociation liquid in tumor organoid culture, the tissue dissociation liquid comprises a basic culture medium component, an antioxidant component, a dissociation enzyme and an additive, and the antioxidant component comprises at least one of taurine, superoxide dismutase and vitamin E. The tumor tissue dissociation liquid is obtained through optimization, the tissue dissociation liquid has high cell separation efficiency on various tumor tissues, the activity of cells can be effectively guaranteed, cell damage is reduced, on the basis, a double-layer sleeve filter screen designed by the application is combined to filter dissociated products, and the dissociation efficiency is improved. The method has the advantages that the method is simple in operation, various tumor organoids can be successfully obtained by using proper organoid culture methods and conditions, the development of cancer fundamental research and clinical transformation research can be greatly promoted by the application, and important support is provided for developing new cancer treatment strategies.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of organoid culture, and in particular to a tumor tissue dissociation solution, a method for dissociating tumor tissue, and applications thereof in culturing tumor organoids. Background Art

[0002] Cancer is one of the leading causes of death worldwide. Isolation and purification of tumor tissue is a key step in tumor research and treatment. Through effective tissue separation methods, high-quality cell samples can be obtained, providing a reliable basis for subsequent genetic analysis, drug screening and personalized treatment. Traditional tissue separation methods usually involve mechanical dissociation and enzymatic treatment. Although cells can be obtained, they often destroy the biological characteristics of cells and affect subsequent research results.

[0003] With the continuous in-depth study of the biological characteristics of tumors, traditional two-dimensional cell culture models have gradually exposed their limitations and are difficult to truly simulate the tumor microenvironment in vivo. Organoid technology is a new three-dimensional culture method developed in recent years. It has the ability of self-renewal and self-organization and is an important tool for studying tissue and organ development, disease mechanisms and drug screening. The emergence of organoid technology provides a new three-dimensional cell culture method for tumor research, which can more realistically reflect the complex structure and function of tumors.

[0004] Therefore, it is of great significance to study methods for efficient dissociation of tumor tissue and cell purification to obtain more tumor cells with fewer impurities, and then combine them with organoid culture construction methods to cultivate them into specific types of organoids. Summary of the invention

[0005] The present invention aims to solve one of the technical problems in the related art at least to a certain extent.

[0006] Therefore, the first aspect of the present invention provides a tumor tissue dissociation fluid. According to an embodiment of the present invention, the tissue dissociation fluid comprises a basic culture medium component, an antioxidant component, a dissociation enzyme and an additive, wherein the antioxidant component comprises at least one of taurine, superoxide dismutase and vitamin E. The tumor tissue dissociation fluid according to the embodiment of the present invention has a high efficiency in dissociating tumor tissue, and the antioxidant substances screened and obtained in this application can fully guarantee the activity of tumor cells. The dissociation fluid plays an important role in subsequent cell culture and tumor organoid culture.

[0007] According to an embodiment of the present invention, the above-mentioned tumor tissue dissociation solution may also include at least one of the following additional technical features: According to an embodiment of the present invention, the concentration of taurine is 1-50 μM, preferably 5-20 μM, and more preferably 10 μM.

[0008] According to an embodiment of the present invention, the concentration of superoxide dismutase is 0-100 nM, preferably 20-80 nM, and more preferably 50 nM.

[0009] According to an embodiment of the present invention, the concentration of vitamin E is 0-100 nM, preferably 20-80 nM, and more preferably 50 nM.

[0010] After screening and optimization, the present application found that adding the above-mentioned antioxidant ingredients and keeping their concentration within the above-mentioned concentration range can protect cells from oxidative damage, maintain the redox balance in cells, and reduce the death of tumor cells during the dissociation process. In addition, the antioxidant ingredients can reduce oxidative stress during cell dissociation, thereby improving the efficiency of cell dissociation, more effectively protecting the health and activity of tumor cells, and making the obtained tumor cells more suitable for subsequent research.

[0011] According to an embodiment of the present invention, the dissociation enzyme includes at least one of collagenase, neutral protease and deoxyribonuclease.

[0012] Dissociative enzymes are a class of enzymes that can decompose macromolecules in the intercellular matrix, thereby dispersing cells. In the present application, dissociative enzymes are used to separate single cells from tumor tissue for subsequent cell culture or other experimental operations. Based on the type of tissue used in the present application, the composition of the extracellular matrix, and the subsequent specific needs for tumor single cells, the composition and concentration of tissue dissociative enzymes are optimized and screened, and the obtained enzymes and their concentrations can more effectively separate single cells while maintaining the activity and function of the cells.

[0013] According to an embodiment of the present invention, the concentration of the collagenase is 30-100 U / mL, preferably 40-80 U / mL, and more preferably 70 U / mL. Collagenase (collagenase) is an enzyme that can specifically recognize and hydrolyze a specific sequence in collagen. It plays an important role in the fields of cell culture and tumor research. The type of collagenase described in this application is not particularly limited, including at least one of type I, type II, type III and type IV, which can be used for the dissociation of different types of tissue samples by ratio.

[0014] According to an embodiment of the present invention, the concentration of the neutral protease is 70-200 μg / mL, preferably 100-150 μg / mL, and more preferably 120 μg / mL. Neutral protease is a non-specific metalloprotease that causes little damage to cells, can maintain cell membrane integrity, and is not affected by temperature, pH, and serum components. This application uses it to separate single cells from tumor tissue. It is known to those skilled in the art that it can also be used for subsequent cell culture, such as separation of primary cells, cell passage, etc.

[0015] According to an embodiment of the present invention, the concentration of the deoxyribonuclease is 1000-5000 U / mL, preferably 2000-4000 U / mL, and more preferably 3000 U / mL. Deoxyribonuclease is an endonuclease that preferentially cleaves the phosphodiester bond adjacent to a pyrimidine nucleotide to produce a 5'-phosphate-terminated polynucleotide with a free hydroxyl group at the 3' position. The enzyme can remove DNA contamination during cell culture.

[0016] According to an embodiment of the present invention, the additive includes at least one of HEPES, bovine serum albumin and Y27632.

[0017] According to an embodiment of the present invention, the concentration of HEPES is 5-15 mM, preferably 8-12 mM, and more preferably 10 mM. The HEPES is a hydrogen ion buffer. HEPES can provide a stable pH environment in the environment inside and outside the tumor cells, which is conducive to the normal growth and metabolism of the cells. During the tumor tissue dissociation process, this stable pH environment helps to protect the cell structure and function and reduce cell damage caused by pH fluctuations.

[0018] According to an embodiment of the present invention, the mass percentage of bovine serum albumin is 0.5%-5%, preferably 0.5%-3%, and more preferably 1%. Bovine serum albumin (BSA) can not only reduce the damage to cells during the dissociation process, but also act as a reaction stabilizer for enzymes, prevent enzyme decomposition and nonspecific adsorption, and improve enzyme stability and cutting efficiency. The concentration of BSA needs to be appropriate, and too high a concentration may inhibit the activity of digestive enzymes.

[0019] According to an embodiment of the present invention, the concentration of Y27632 is 5-20 μM, preferably 5-15 μM, and more preferably 10 μM. Y27632 is a highly efficient, selective, ATP-competitive anti-apoptotic factor ROCK inhibitor. Y27632 can inhibit the activity of ROCK in tissue dissociation, reduce cell anoikis, promote cell proliferation, maintain cell function, protect cells from damage during dissociation, and regulate the cytoskeleton, thereby improving the survival rate and function of cells after dissociation.

[0020] According to an embodiment of the present invention, the additive further includes an antibacterial component.

[0021] According to an embodiment of the present invention, the antibacterial component is an antibiotic. Adding antibiotics can effectively prevent bacterial and fungal contamination.

[0022] According to an embodiment of the present invention, the antibiotic includes at least one of gentamicin, amphotericin, penicillin and streptomycin.

[0023] According to an embodiment of the present invention, the concentration of gentamicin is 50-500 μg / mL, preferably 50-200 μg / mL, and more preferably 100 μg / mL.

[0024] According to an embodiment of the present invention, the concentration of amphotericin is 1-5 μg / mL, preferably 1-3 μg / mL, and more preferably 2.5 μg / mL.

[0025] According to an embodiment of the present invention, the concentration of penicillin is 50-500 U / mL, preferably 50-200 U / mL, and more preferably 100 U / mL.

[0026] According to an embodiment of the present invention, the concentration of streptomycin is 50-500 μg / mL, preferably 50-200 μg / mL, and more preferably 100 μg / mL.

[0027] According to an embodiment of the present invention, the basic culture medium includes any one selected from Advanced DMEM / F12, Ham's F-12, SILAC Advanced DMEM / F-12 Flex, DMEM / F-12, and William's E culture medium.

[0028] In the second aspect of the present invention, the present invention proposes the use of the tumor tissue dissociation solution described in the first aspect in dissociating tumor tissue, wherein the tumor tissue includes at least one of lung adenocarcinoma tissue, colorectal cancer tissue, and breast cancer tissue. The tumor tissue dissociation solution according to the embodiment of the present invention has a high efficiency in dissociating tumor tissue, and the antioxidant substances screened and obtained in this application can fully guarantee the activity of tumor cells. The dissociation solution plays an important role in subsequent cell culture and tumor organoid culture, and the operation method is simple and the effect is stable.

[0029] In the third aspect of the present invention, the present invention proposes the use of the tumor tissue dissociation fluid described in the first aspect in culturing tumor organoids, wherein the tumor organoids include at least one of lung adenocarcinoma organoids, colorectal cancer organoids, and breast cancer organoids. The tumor tissue dissociation fluid according to the embodiment of the present invention can be effectively used in the culture process of organoids, that is, the cultured organoids combine efficient tissue separation technology and organoid culture technology, which not only improves cell activity and separation efficiency, but also reduces cell damage, and then through the organoid construction method obtained in this application, the three-dimensional structure and biological characteristics of the tumor in the body are successfully simulated. According to a specific embodiment of the present invention, the tumor tissue dissociation fluid described in this application can be used to effectively dissociate lung adenocarcinoma, colorectal cancer and breast cancer tissues, and the single cells obtained after dissociation are successfully cultured into lung adenocarcinoma organoids, colorectal cancer organoids and breast cancer organoids.

[0030] According to an embodiment of the present invention, the use comprises: (a) using the tumor tissue dissociation solution described in the first aspect to dissociate the tumor tissue to obtain tumor cell clusters or single cells; (b) filtering the tumor cell cluster or single cell through a double-layer sleeve filter to obtain a filtered single cell precipitate; (c) culturing the single cell pellet in a tumor organoid culture medium to obtain the tumor organoid.

[0031] In the fourth aspect of the present invention, the present invention proposes a method for dissociating tumor tissue. According to an embodiment of the present invention, the method comprises: dissociating the tumor tissue to be dissociated in the tumor tissue dissociation solution described in the first aspect. As mentioned above, the efficiency of dissociating tumor tissue by the tumor tissue dissociation solution according to the embodiment of the present invention is high, and the antioxidant substances screened and obtained in this application can fully guarantee the activity of tumor cells. The dissociation solution plays an important role in subsequent cell culture and tumor organoid culture, and the method is simple to operate and has stable effects.

[0032] According to an embodiment of the present invention, the above method for dissociating tumor tissue may further include at least one of the following additional technical features: According to an embodiment of the present invention, the tumor tissue is preliminarily subjected to a washing treatment and / or a shearing treatment.

[0033] According to an embodiment of the present invention, the washing treatment is performed using a basic culture medium, and the number of washing times is 2 to 5 times, preferably 3 times.

[0034] According to an embodiment of the present invention, the basic culture medium includes any one selected from Advanced DMEM / F12, Ham's F-12, SILAC Advanced DMEM / F-12 Flex, DMEM / F-12, and William's E culture medium.

[0035] According to an embodiment of the present invention, the dissociation is performed at 37° C. with shaking.

[0036] According to an embodiment of the present invention, the dissociation time is 5-10 min.

[0037] In a fifth aspect of the present invention, the present invention provides a method for constructing a tumor organoid. According to an embodiment of the present invention, the method comprises: (a) dissociating tumor tissue using the method described in the fourth aspect to obtain tumor cell clusters or single cells; (b) filtering the tumor cell cluster or single cell through a double-layer sleeve filter to obtain a filtered single cell precipitate; (c) culturing the single cell pellet in a tumor organoid culture medium to obtain the tumor organoid.

[0038] The method according to the embodiment of the present invention not only combines the efficient tissue separation technology described in the fourth aspect, but also uses the double-layer sleeve filter and organoid culture technology designed by the present application, which can remove immune cells at one time, not only improves cell activity and separation efficiency, but also reduces tumor cell damage. The organoid construction method obtained by the present application successfully simulates the three-dimensional structure and biological characteristics of tumors in the body.

[0039] According to an embodiment of the present invention, the double-layer sleeve filter comprises an upper filter and a lower filter, wherein the diameter of the filter holes in the upper filter is 50-100 μm, and the diameter of the filter holes in the lower filter is 10-40 μm.

[0040] According to an embodiment of the present invention, the diameter of the filter holes in the upper filter screen is 60-80 μm, and the diameter of the filter holes in the lower filter screen is 10-30 μm.

[0041] According to an embodiment of the present invention, the diameter of the filter holes in the upper filter screen is 70 μm, and the diameter of the filter holes in the lower filter screen is 20 μm.

[0042] The double-layer sleeve filter adopts a sleeve design, which is small at the top and large at the bottom, and can be disassembled and assembled. It is a device designed by the present application. For specific structure, refer to Figure 1 . The cells dissociated from tumor tissue include tumor cell clusters, lymphocytes, monocytes, granulocytes, red blood cells and immune cells. Different types of cells have different sizes. The diameter of tumor cell clusters is 40-60 μm, and the diameter of lymphocytes is generally between 6-10 μm; the diameter of monocytes is about 12-20 μm, the diameter of granulocytes is about 12-18 μm, the diameter of red blood cells is 7 μm, and the diameter of immune cells is 10-18 μm. The upper filter of the sleeve can remove incompletely dissociated tissue blocks and large cell impurities to ensure the yield of separated cells. The lower filter can remove red blood cells and various immune-related cells in the cells to ensure the purity of the separated cells. The sleeve design can separate and purify tumor cells at one time, greatly improving the efficiency of the experiment.

[0043] According to an embodiment of the present invention, the tumor organoid includes an organoid of any tumor. Those skilled in the art will appreciate that the structure and composition of tumor tissues are not very different. In the case of similar structures and components, based on the results verified by this application, the tumors that can be dissociated by the tumor tissue dissociation fluid are not particularly limited.

[0044] According to some specific embodiments of the present invention, the tumor organoid comprises at least one of a lung adenocarcinoma organoid, a colorectal cancer organoid, and a breast cancer organoid.

[0045] According to an embodiment of the present invention, the culturing is carried out under the conditions of 37°C and 5% CO2.

[0046] The beneficial effects of the present invention include at least: (1) The method for tumor tissue dissociation mentioned in the present invention is simple and stable. In the tissue dissociation step, the antioxidant added to the dissociation solution can fully guarantee the activity of tumor cells and obtain tumor cells with higher activity.

[0047] (2) The method for constructing tumor organoids proposed in the present invention combines efficient tissue separation, purification technology and organoid culture technology, which not only improves cell activity and separation efficiency, but also reduces cell damage, providing an efficient and accurate tool for tumor research and personalized treatment. The high activity and high purity of cells are guaranteed by optimized tissue dissociation fluid and purification methods; the three-dimensional structure and biological characteristics of tumors in the body are successfully simulated by scientific organoid construction methods. The application of the present invention will greatly promote the development of basic cancer research and clinical translational research, and provide important support for the development of new cancer treatment strategies.

[0048] Additional aspects and advantages of the present invention will be given in part in the following description and in part will be obvious from the following description, or will be learned through practice of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS

[0049] The above and / or additional aspects and advantages of the present invention will become apparent and easily understood from the description of the embodiments in conjunction with the following drawings, in which: Figure 1 is a schematic diagram of the process of lung adenocarcinoma tissue dissociation and digestion and lung adenocarcinoma organoid construction in Example 1 of the present invention; Figure 2 It is an optical microscope bright field image of lung adenocarcinoma organoids constructed after lung adenocarcinoma tissue was dissociated and digested using tissue dissociation solution 1 in Example 1 of the present invention and cultured for 0, 3, 5, and 7 days, scale bar: 200 μm; Figure 3 It is an optical microscope bright field image of lung adenocarcinoma organoids constructed after lung adenocarcinoma tissue was dissociated and digested using tissue dissociation solution 2 in Example 1 of the present invention, cultured for 0, 3, 5, and 7 days, scale bar: 200 μm; Figure 4 It is an optical microscope bright field image of lung adenocarcinoma organoid cultured on days 0, 3, 5, and 7 of the lung adenocarcinoma tissue dissociated and digested by Thermo TrypLE™ Express enzyme in Example 1 of the present invention, scale bar: 200 μm; Figure 5 This is a diagram showing the immunohistochemistry results of lung adenocarcinoma organoids constructed after lung adenocarcinoma tissue was dissociated and digested using tissue dissociation solution 1 in Example 1 of the present invention, scale bar: 50 μm; Figure 6 It is an optical microscope bright field image of the colorectal cancer organoid cultured on days 0, 3, 5, and 7 after the colorectal cancer tissue was dissociated and digested using tissue dissociation solution 1 in Example 2 of the present invention, scale bar: 200 μm; Figure 7 : is the immunohistochemical result of colorectal cancer organoid constructed after colorectal cancer tissue was dissociated and digested by tissue dissociation solution 1 in Example 2 of the present invention, scale bar: 100 μm; Figure 8 It is an optical microscope bright field image of breast cancer organoid culture constructed by dissociating and digesting breast cancer tissue using tissue dissociation solution 1 in Example 3 of the present invention on the 0th, 3rd and 6th days of primary culture (P0) and the 3rd, 6th and 11th days after passage (P1), scale bar: 100 μm; Fig. 9 This is an immunofluorescence result diagram of breast cancer organoids constructed after breast cancer tissue was dissociated and digested by tissue dissociation solution 1 in Example 3 of the present invention. Scale bar: 500 μm. DETAILED DESCRIPTION

[0050] The embodiments of the present invention are described in detail below. The embodiments described below are exemplary and are only used to explain the present invention, and should not be construed as limiting the present invention.

[0051] It should be noted that the terms "first" and "second" are used for descriptive purposes only and should not be understood as indicating or implying relative importance or implicitly indicating the number of the indicated technical features. Therefore, the features defined as "first" and "second" may explicitly or implicitly include one or more of the features. Further, in the description of the present invention, unless otherwise specified, the meaning of "plurality" is two or more.

[0052] The endpoints and any values ​​of the ranges disclosed in this article are not limited to the precise ranges or values, and these ranges or values ​​should be understood to include values ​​close to these ranges or values. For numerical ranges, the endpoint values ​​of each range, the endpoint values ​​of each range and the individual point values, and the individual point values ​​can be combined with each other to obtain one or more new numerical ranges, which should be considered as specifically disclosed in this article.

[0053] In order to make the present invention more easily understood, certain technical and scientific terms are specifically defined below. Unless otherwise clearly defined elsewhere in this document, all other technical and scientific terms used herein have the meanings commonly understood by those skilled in the art to which the present invention belongs.

[0054] In this document, the terms “include” or “comprising” are open expressions, that is, including the contents specified in the present invention but not excluding other contents.

[0055] As used herein, the terms "optionally", "optional" or "optionally" generally mean that the subsequently described event or circumstance may but need not occur, and that the description includes instances where the event or circumstance occurs and instances where it does not.

[0056] In this article, the term "organoid" refers to an in vitro 3D culture that can simulate the three-dimensional structure and physiological function of organs (or tissues) in the body under normal (or disease) conditions. In layman's terms, organoids are three-dimensional cell cultures. Stem cells are cultured in matrix gel. Under the action of chemical small molecule inhibitors / activators, cytokines, culture medium additives and other substances, the resulting tissue structure is similar to the corresponding organ. It has the characteristics of cell proliferation and differentiation, self-renewal, self-assembly, long-term culture, and genetic stability.

[0057] In this article, the concentration and percentage of each reagent in the tumor tissue dissociation fluid refer to the final concentration and final percentage of the reagent in the tumor tissue dissociation fluid. For example, in the tumor tissue dissociation fluid, the concentration of superoxide dismutase is 50 nM, which means that the final concentration of superoxide dismutase in the tumor tissue dissociation fluid is 50 nM.

[0058] The scheme of the present disclosure will be explained below in conjunction with the examples. Those skilled in the art will appreciate that the following examples are only used to illustrate the present disclosure and should not be considered to limit the scope of the present disclosure. Where specific techniques or conditions are not indicated in the examples, the techniques or conditions described in the literature in this area or the product instructions are used. Where the manufacturers of reagents or instruments are not indicated, they are all conventional products that can be obtained commercially.

[0059] The sources of the reagents used in the examples of this application are shown in Table 1.

[0060] Table 1

[0061] Example 1 Lung adenocarcinoma tissue dissociation and organoid construction Prepare tissue dissociation solution according to the following recipe: Tissue dissociation solution 1: Add 10 mM HEPES, 10 μM taurine, 50 nM superoxide dismutase, 50 nM vitamin E, 70 U / mL collagenase, 120 μg / mL neutral proteinase, 3000 U / mL deoxyribonuclease, 1% bovine serum albumin, 10 μM Y27632, 100 μg / mL gentamicin, 2.5 μg / mL amphotericin, 100 U / mL penicillin, and 100 μg / mL streptomycin to Advanced DMEM / F12 medium.

[0062] Tissue dissociation solution 2: Add HEPES at a final concentration of 10 mM, 70 U / mL collagenase, 120 μg / mL neutral proteinase, 3000 U / mL deoxyribonuclease, 1% bovine serum albumin, 10 μM Y27632, 100 μg / mL gentamicin, 2.5 μg / mL amphotericin, 100 U / mL penicillin, and 100 μg / mL streptomycin to Advanced DMEM / F12 medium.

[0063] Tissue dissociation and digestion enzymes: Thermo TrypLE™ Express enzymes.

[0064] The above dissociation solution and tissue digestion enzymes were used to digest lung adenocarcinoma tissue and construct lung adenocarcinoma organoids. The method is referenced Figure 1 , the specific steps are as follows: (1) Fresh lung adenocarcinoma tumor surgical resection specimens obtained clinically were placed in the prepared pre-cooled tumor tissue preservation solution and sent to the laboratory for pretreatment within 12 hours.

[0065] (2) Sample washing: Transfer the above tissues into a 15 mL centrifuge tube, then wash with 5 mL of Advanced DMEM / F12 medium for 30 s, remove the supernatant, and add 5 mL of Advanced DMEM / F12 medium for washing again. Repeat the above method for 3 times to remove impurities on the tissue surface.

[0066] (3) Sample cutting: In a biosafety cabinet, transfer the sample to a 6 cm culture dish and cut the tissue into pieces of 1-3 mm in size using sterilized surgical scissors on ice. 3 .

[0067] (4) Tissue digestion: Transfer the chopped tissue to a 15 mL centrifuge tube, divide it into three equal parts, add 10 mL of tissue dissociation solution to each tube, and digest it at 37°C for 5-10 min. After the dissociation and digestion, add FBS with a final concentration of 2% to terminate the dissociation and digestion, then centrifuge at 300 g for 3 min, retain the precipitate and remove the supernatant.

[0068] (5) Cell filtration: The digestion solution in step (4) is filtered Figure 1 Filter the cell suspension through the double-layer sleeve filter (the pore size of the upper filter is 70 μm, and the pore size of the lower filter is 20 μm), gently rinse and collect the cell clumps on the middle filter. Centrifuge the collected cell solution at 300 g for 3 min, and carefully remove the supernatant to obtain the cell precipitate.

[0069] (6) Take an appropriate amount of matrix gel to resuspend the cell pellet and use a pipette to drop the gel mixed with cells into a 24-well plate, with about 25 μL per well.

[0070] (7) Place the culture plate inoculated with the gel droplets in a CO2 incubator and let it stand for 15-20 min until it fully solidifies.

[0071] (8) Add lung adenocarcinoma organoid culture medium to the culture dish, place it in a constant temperature incubator at 37°C and 5% CO2, replace the culture medium every 2 days, and observe the growth status of lung adenocarcinoma organoids under an inverted optical microscope. The results are as follows: Figure 2 , 3 , 4. The organoids were vesicular, with obvious cavities and thick cavities. In addition, the obtained lung adenocarcinoma organoids were subjected to immunohistochemical detection using conventional methods in the art. The results are shown in Figure 5 As shown in the figure, Ki67 is a marker for mitotic cells; TTF1 is thyroid transcription factor-1, which is expressed in the nuclei of thyroid follicular epithelial and alveolar epithelial cells, and is expressed in about 75%-85% of lung adenocarcinomas; NapsinA is a new aspartic proteinase A, which is expressed in normal alveolar type II epithelial cells and proximal and distal renal tubules, and more than 80% is expressed in lung adenocarcinomas. TTF1 and NapsinA are common specific markers for lung adenocarcinoma. In immunohistochemical detection, it was observed that almost all cells in lung adenocarcinoma organoids can be marked by TTF1 and NapsinA.

[0072] Example 2 Dissociation of colorectal cancer tumor tissue and construction of organoids In this example, the tissue dissociation solution 1 in Example 1 was used to dissociate clinically obtained colorectal cancer tumor tissues, and colorectal cancer organoids were constructed. The specific experimental steps are as follows: (1) Place fresh colorectal cancer tumor surgical resection specimens in the prepared pre-cooled tumor tissue preservation solution and send them to the laboratory for pretreatment within 12 hours.

[0073] (2) Sample washing: Transfer the above tissues into a 15 mL centrifuge tube, then wash with 5 mL of Advanced DMEM / F12 medium for 30 s, remove the supernatant, and add 5 mL of Advanced DMEM / F12 medium for washing again. Repeat the above method for 3 times to remove impurities on the tissue surface.

[0074] (3) Sample cutting: In a biosafety cabinet, transfer the sample to a 6 cm culture dish and cut the tissue into pieces of 1-3 mm in size using sterilized surgical scissors on ice. 3 .

[0075] (4) Tissue digestion: Transfer the chopped tissue to a 15 mL centrifuge tube, add 10 mL of tissue dissociation solution and digest at 37°C for 10 minutes. After the dissociation and digestion, add FBS with a final concentration of 2% to terminate the dissociation and digestion, then centrifuge at 300g for 3 minutes, retain the precipitate and remove the supernatant.

[0076] (5) Cell filtration: The digestion solution in step (4) is filtered Figure 1 Filter the cell suspension through the double-layer sleeve filter (the pore size of the upper filter is 70 μm, and the pore size of the lower filter is 20 μm), gently rinse and collect the cell clumps on the middle filter. Centrifuge the collected cell solution at 300 g for 3 min, and carefully remove the supernatant to obtain the cell precipitate.

[0077] (6) Take an appropriate amount of matrix gel to resuspend the cell pellet and use a pipette to drop the gel mixed with cells into a 24-well plate, with about 25 μL per well.

[0078] (7) Place the culture plate inoculated with the gel droplets in a CO2 incubator and let it stand for 15-20 min until it fully solidifies.

[0079] (8) Add colorectal cancer organoid culture medium to the culture dish, place it in a constant temperature incubator and culture it at 37°C and 5% CO2 concentration. Replace the culture medium every 2 days. On the 0th, 3rd, 5th, and 7th days of culture, observe the growth status of the colorectal cancer organoids under an inverted optical microscope. The results are as follows: Figure 6 As shown in Figure 1, the organoids are relatively solid cystic structures in the early stages of growth, and gradually become vacuolar structures with thin walls and larger cavities as they grow. In addition, the obtained colorectal cancer organoids were subjected to immunohistochemical detection using conventional methods in the field. The results are shown in Figure 1. Figure 7 As shown in the figure, Ki67 is a marker for cells in the mitotic phase; CDX2 is an intestinal-specific nuclear transcription factor, and the ectopic expression of CDX2 is closely related to pathological conditions such as gastrointestinal epithelial metaplasia, chronic mucosal inflammation, and adenocarcinoma; CK20 (cytokeratin 20) mainly marks gastrointestinal epithelial cells, and in gastrointestinal adenocarcinoma, CK20 is usually positive. In immunohistochemical detection, it was observed that both CDX2 and CK20 were positively expressed in colorectal cancer organoids.

[0080] Example 3 Dissociation of breast cancer tumor tissue and construction of organoids In this example, the tissue dissociation solution 1 in Example 1 was used to dissociate clinically obtained breast cancer tumor tissues and construct breast cancer organoids. The specific experimental steps are as follows: (1) Place fresh breast cancer tumor specimens removed by surgery in the prepared pre-cooled tumor tissue preservation solution and send them to the laboratory for pretreatment within 12 hours.

[0081] (2) Sample washing: Transfer the above tissues into a 15 mL centrifuge tube, then wash with 5 mL of Advanced DMEM / F12 medium for 30 s, remove the supernatant, and add 5 mL of Advanced DMEM / F12 medium for washing again. Repeat the above method for 3 times to remove impurities on the tissue surface.

[0082] (3) Sample cutting: In a biosafety cabinet, transfer the sample to a 6 cm culture dish and cut the tissue into pieces of 1-3 mm in size using sterilized surgical scissors on ice. 3 .

[0083] (4) Tissue digestion: Transfer the chopped tissue to a 15 mL centrifuge tube, add 10 mL of dissociation digestion solution and shake digest at 37°C for 10-15 minutes. After digestion, add FBS with a final concentration of 2% to terminate digestion, then centrifuge at 300 g for 3 min, retain the precipitate and remove the supernatant.

[0084] (5) Cell filtration: The digestion solution in step (4) is filtered Figure 1 Filter the cell suspension through the double-layer sleeve filter (the pore size of the upper filter is 70 μm, and the pore size of the lower filter is 20 μm), gently rinse and collect the cell clumps on the middle filter. Centrifuge the collected cell solution at 300 g for 3 min, and carefully remove the supernatant to obtain the cell precipitate.

[0085] (6) Take an appropriate amount of matrix gel to resuspend the cell pellet and use a pipette to drop the gel mixed with cells into a 24-well plate, with about 25 μL per well.

[0086] (7) Place the culture plate inoculated with the gel droplets in a CO2 incubator and let it stand for 15-20 min until it fully solidifies.

[0087] (8) Add breast cancer organoid culture medium to the culture dish and culture it in a constant temperature incubator at 37°C and 5% CO2. Change the culture medium every 2 days. Observe the growth status of breast cancer organoids under an inverted optical microscope on days 0, 3, and 6 of primary culture (P0) and days 3, 6, and 11 after the first passage (P1). Figure 8 As shown in Figure 1, breast cancer organoids present an irregular solid spherical structure, some organoids present a tubular structure, and cells aggregate to form nodules. In addition, the obtained breast cancer organoids were subjected to immunofluorescence detection using a conventional method in the art. The results are shown in Figure 1. Fig. 9 As shown, DAPI marks the cell nucleus. ER (estrogen receptor) and PR (hormone receptor) belong to the nuclear hormone receptor family. After binding to the ligand, they function as transcription factors and play an important role in the occurrence and development of breast cancer. In immunofluorescence detection, it was observed that both ER and PR were positively expressed in breast cancer organoids.

[0088] In the description of this specification, the description with reference to the terms "one embodiment", "some embodiments", "example", "specific example", or "some examples" etc. means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representations of the above terms do not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described may be combined in any one or more embodiments or examples in a suitable manner. In addition, those skilled in the art may combine and combine different embodiments or examples described in this specification and the features of different embodiments or examples, unless they are contradictory.

[0089] Although the embodiments of the present invention have been shown and described above, it is to be understood that the above embodiments are exemplary and are not to be construed as limitations of the present invention. A person skilled in the art may change, modify, replace and vary the above embodiments within the scope of the present invention.

Claims

1. A tumor tissue dissociation fluid, characterized in that: The tissue dissociation fluid comprises a basic culture medium component, an antioxidant component, a dissociation enzyme and an additive, wherein the antioxidant component comprises at least one of taurine, superoxide dismutase and vitamin E.

2. The tumor tissue dissociation fluid according to claim 1, characterized in that The concentration of taurine is 1-50 μM; and / or The concentration of superoxide dismutase is 0-100 nM; and / or The concentration of vitamin E is 0-100 nM.

3. The tumor tissue dissociation solution according to claim 1, characterized in that The dissociation enzyme comprises at least one of collagenase, neutral protease and deoxyribonuclease; and / or The additive comprises at least one of HEPES, bovine serum albumin and Y27632; and / or The basic culture medium includes any one selected from Advanced DMEM / F12, Ham's F-12, SILAC Advanced DMEM / F-12 Flex, DMEM / F-12, and William's E culture medium.

4. The tumor tissue dissociation solution according to claim 1, characterized in that The additive includes an antimicrobial component.

5. The tumor tissue dissociation fluid according to claim 3, characterized in that: The concentration of the collagenase is 30-100 U / mL; and / or The concentration of the neutral protease is 70-200 μg / mL; and / or The concentration of the deoxyribonuclease is 1000-5000 U / mL.

6. The tumor tissue dissociation solution according to claim 3, characterized in that: The concentration of HEPES is 5-15 mM; and / or The mass percentage of the bovine serum albumin is 0.5%-5%; and / or The concentration of Y27632 is 5-20 μM.

7. The tumor tissue dissociation solution according to claim 4, characterized in that: The antibacterial component is an antibiotic.

8. The tumor tissue dissociation solution according to claim 7, characterized in that: The antibiotics include at least one of gentamicin, amphotericin, penicillin and streptomycin.

9. Use of the tumor tissue dissociation solution according to any one of claims 1 to 8 in dissociating tumor tissue, wherein the tumor tissue comprises at least one of lung adenocarcinoma tissue, colorectal cancer tissue and breast cancer tissue.

10. Use of the tumor tissue dissociation fluid according to any one of claims 1 to 8 in culturing tumor organoids, wherein the tumor organoids include at least one of lung adenocarcinoma organoids, colorectal cancer organoids and breast cancer organoids.

11. A method for dissociating tumor tissue, characterized in that: The method comprises: dissociating the tumor tissue to be dissociated in the tumor tissue dissociation solution according to any one of claims 1 to 8.

12. A method for constructing tumor organoids, characterized in that: include: (a) dissociating the tumor tissue using the method for dissociating tumor tissue according to claim 11 to obtain tumor cell clusters or single cells; (b) filtering the tumor cell cluster or single cell through a double-layer sleeve filter to obtain a filtered single cell precipitate; (c) culturing the single cell pellet in a tumor organoid culture medium to obtain the tumor organoid.

13. The method for constructing tumor organoids according to claim 12, characterized in that: The double-layer sleeve filter comprises an upper filter and a lower filter, wherein the diameter of the filter holes in the upper filter is 50-100 μm, and the diameter of the filter holes in the lower filter is 10-40 μm.

14. The method for constructing tumor organoids according to claim 13, characterized in that: The tumor organoids include at least one of lung adenocarcinoma organoids, colorectal cancer organoids, and breast cancer organoids.

Citation Information

Patent Citations

  • Young porcine islet isolation method and digestive juice for isolation

    CN107119008A

  • Method for separating and extracting fiber cells from mouse heart

    CN114149964A

  • Combined reagent, kit, method for detecting organoid activity and drug sensitivity and screening drugs by using combined reagent and kit, and application of combined reagent and kit

    CN117402930A

  • Organ-like tissue digestive juice

    CN117551599A

  • Ex vivo maturation of islet cells

    US20150132849A1

Cited By

  • Tissue dissociation liquid, tissue dissociation method and application of tissue dissociation liquid

    CN121538173A